Rigenera® Device
Patented medical device for mechanical disaggregation of autologous tissue biopsies.
Patented medical device for mechanical disaggregation of autologous tissue biopsies.
Progenitor cells, Human Smart Exosomes and extracellular matrix extracted in one closed process.
Immediate injection of the solution into affected scalp zones with no delay and no manipulation.
Androgenetic alopecia is characterized by progressive follicular miniaturization driven by DHT-mediated signaling at the dermal papilla. The AMT® approach aims to restore the follicular niche microenvironment by replenishing progenitor cells and paracrine mediators.
The mastoid area is biologically DHT-insensitive, providing a reliable source of healthy tissue. The mechanical disaggregation protocol preserves cell viability, exosome integrity, and extracellular matrix architecture.
Human Smart Exosomes within the AMT® triad carry tissue-specific bioactive cargo including growth factors, microRNAs, and signaling proteins that help modulate inflammation, stimulate follicular stem cell activity, and promote anagen re-entry.
The only system with CE-marked autologous micrografting and no regulatory alternative.
Fully mechanical process with no enzymes, no culture, no expansion, and no cryopreservation required.
Autologous exosomes matched to the patient's own biology, not pooled donors or cell lines.
From biopsy to injection in a single session with no laboratory downtime.
Scientifically validated exosome yield per treatment, first in the market to quantify this.
Complete in-office procedure with no lab required and no pre-processing downtime.
Androgenetic alopecia (AGA), male or female pattern.
Preference for an autologous, minimally invasive approach.
Patients seeking adjunctive therapy to pharmacological treatment.
Post-transplant scalp maintenance and follicular support.
Early to moderate thinning with preserved follicular units.
Patients suitable for periodic in-office regenerative maintenance.
Active scalp infections including bacterial, fungal, or viral conditions.
Autoimmune alopecias such as alopecia areata, totalis, or universalis.
Scarring alopecias including lichen planopilaris and frontal fibrosing alopecia.
Active systemic inflammatory disease or uncontrolled comorbidities.
Pregnancy or breastfeeding.
Diffuse unpatterned alopecia (DUPA) as a relative contraindication.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s